Catalog No.: PC-49176Not For Human Use, Lab Use Only.
Vidofludimus calcium (IMU-838) is a selective and potent second-generation dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 160 nM, shows anti-SARS-CoV-2 activity with EC50 of 7.6 uM in Vero cells.
Vidofludimus calcium (IMU-838) is a selective and potent second-generation dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 160 nM, shows anti-SARS-CoV-2 activity with EC50 of 7.6 uM in Vero cells.
Vidofludimus inhibits T cell proliferation with EC50 of 11.8 uM, with a similar effect on CpG ODN 2006-PTO dependent B cell proliferation.
Vidofludimus is specific for human DHODH and does not have off-target effect on kinases, is about 7.5-fold and about 64.4-fold more active on human DHODH as compared to rat DHODH and mouse DHODH, respectively.
Vidofludimus inhibits specifically IL–17F, IL–17A and IFN-g expression in PBMCs.
Vidofludimus is 2.6 times more potent in inhibiting DHO oxidation by human DHODH compared to teriflunomide (IC50=420 nM).
Vidofludimus shows inhibition of rat EAE motor signs in a rat experimental autoimmune encephalomyelitis (EAE) model.
Vidofludimus exerts a broad-spectrum activity against a selection of major human pathogenic viruses.
Physicochemical Properties
M.Wt
375.40
Formula
C20H18FNO4.1/2Ca
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
1-Cyclopentene-1-carboxylic acid, 2-[[(3-fluoro-3′-methoxy[1,1′-biphenyl]-4-yl)amino]carbonyl]-, calcium salt (2:1)
References
1. Muehler A, et al. Mult Scler Relat Disord. 2020 Aug;43:102129.
2. Hahn F, et al. Viruses. 2020 Dec 5;12(12):1394.
